HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human
HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human

Immobilized HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human, His Tag at 1 μg/ml(100 μl/well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Antibody, hFc Tag with the EC50 of 6.7 ng/ml determined by ELISA.

HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human

The purity of HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human was greater than 95% as determined by SEC-HPLC.

HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human

HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.

HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human

The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of malignant tumors that highly express LMP2.
Z06569
¥208,928.00

Ask us a question
Product Introduction
Species Human
Protein Construction
HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer [Gly25-Thr305 (HLA-A*02:01), Ile21-Met119 (B2M) and CLGGLLTMV peptide]
Accession # A0A140T913(HLA-A*02:01)&P61769(B2M)&CLGGLLTMV		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human at 1μg/ml (100μl/Well) on the plate can bind Anti­HLA­A*02:01&B2M&LMP2 (CLGGLLTMV) Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 258 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human
    • HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human

    Immobilized HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human, His Tag at 1 μg/ml(100 μl/well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Antibody, hFc Tag with the EC50 of 6.7 ng/ml determined by ELISA.

  • HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human
    • HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human

    The purity of HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human was greater than 95% as determined by SEC-HPLC.

  • HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human
    • HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human

    HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.


Background
Target Background The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of malignant tumors that highly express LMP2.
Synonyms MHC; RMF; LMP2; LMP-2; Macropain chain 7; Proteasome chain 7; PSMB9; RING12

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.